The pharmaceuticals major is under the USFDA scanner, with the US regulator raising an import alert on the company’s export-oriented unit at Waluj, Aurangabad.
This is the first setback to the Mumbai-based company since it exited a corporate debt restructuring programme in 2009, when its debt touched Rs 3,800 crore. In 2009, the company had defaulted on $110 million of foreign currency convertible bond payments.
Also Read
The stock had slipped 20% to its lower circuit of Rs 1,312 on Thursday.
The stock opened at Rs 1,199 and touched a low of Rs 1,066. Around 1,36,000 shares have already been traded on the BSE so far, as against a two week average of 71,000 shares.